Oncolytic virus treatment differentially affects the CD56

Authors :: Michelle, Wantoch
Erica B, Wilson
Alastair P, Droop
Sarah L, Phillips
Matt, Coffey
Yasser M, El-Sherbiny
Tim D, Holmes
Alan A, Melcher
Laura F, Wetherill
Graham P, Cook
Source :: ImmunologyREFERENCES. 166(1)
Publication Year :: 2021
Abstract: Natural killer (NK) cells protect against intracellular infection and cancer. These properties are exploited in oncolytic virus (OV) therapy, where antiviral responses enhance anti-tumour immunity. We have analysed the mechanism by which reovirus, an oncolytic dsRNA virus, modulates human NK cell activity. Reovirus activates NK cells in a type I interferon (IFN-I) dependent manner, inducing STAT1 and STAT4 signalling in both CD56